145 related articles for article (PubMed ID: 38537314)
21. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients.
Wu Q; Wang Z; Luo Y; Xie X
BMC Immunol; 2023 Sep; 24(1):27. PubMed ID: 37658314
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort.
Taïeb J; Sayah L; Heinrich K; Kunzmann V; Boileve A; Cirkel G; Lonardi S; Chibaudel B; Turpin A; Beller T; Hautefeuille V; Vivaldi C; Mazard T; Bauguion L; Niger M; Prager GW; Coutzac C; Benedikt Westphalen C; Auclin E; Pilla L
Eur J Cancer; 2023 Jul; 188():90-97. PubMed ID: 37229836
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer.
Mazzoli G; Cohen R; Lonardi S; Corti F; Elez E; Fakih M; Jayachandran P; Colle R; Shah AT; Salati M; Fenocchio E; Salvatore L; Ambrosini M; Ros J; Intini R; Cremolini C; Overman MJ; André T; Pietrantonio F
Eur J Cancer; 2022 Sep; 172():171-181. PubMed ID: 35777274
[TBL] [Abstract][Full Text] [Related]
25. Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability.
Boyer C; Sefrioui D; Cohen R; Chautard R; Perrier M; Lebrun H; Goujon G; Hautefeuille V; Dior M; Walter T; Mary F; Manfredi S; Caroli-Bosc FX; Cervantes B; Coriat R; Deluche E; Zaanan A; Olivier R; Bouché O; Piessen G; Lecomte T; Louvet C; Michel P; Aparicio T; André T; Taieb J; Randrian V; Tougeron D
Dig Liver Dis; 2023 Jan; 55(1):123-130. PubMed ID: 35397988
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
Front Immunol; 2022; 13():795972. PubMed ID: 35371084
[TBL] [Abstract][Full Text] [Related]
27. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.
Cohen R; Bennouna J; Meurisse A; Tournigand C; De La Fouchardière C; Tougeron D; Borg C; Mazard T; Chibaudel B; Garcia-Larnicol ML; Svrcek M; Vernerey D; Menu Y; André T
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33148693
[TBL] [Abstract][Full Text] [Related]
28. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.
Li J; Deng Y; Zhang W; Zhou AP; Guo W; Yang J; Yuan Y; Zhu L; Qin S; Xiang S; Lu H; Gong J; Xu T; Liu D; Shen L
J Hematol Oncol; 2021 Jun; 14(1):95. PubMed ID: 34154614
[TBL] [Abstract][Full Text] [Related]
29. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibitors for patients with isolated peritoneal carcinomatosis from dMMR/MSI-H colorectal cancer, a BIG-RENAPE collaboration.
Barraud S; Tougeron D; Villeneuve L; Eveno C; Bayle A; Parc Y; Pocard M; André T; Cohen R
Dig Liver Dis; 2023 May; 55(5):673-678. PubMed ID: 36266207
[TBL] [Abstract][Full Text] [Related]
31. Real-World Treatment Patterns and Clinical Outcomes for Standard of Care Regimens in Patients with Deficient MMR or MSI-High Metastatic Colorectal and Non-Colorectal Cancer: A Retrospective Chart Review Study in France.
Roset M; Amonkar M; Patel R; Lara N; Kothari S
Adv Ther; 2022 Mar; 39(3):1215-1229. PubMed ID: 35025060
[TBL] [Abstract][Full Text] [Related]
32. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors.
Corti F; Lonardi S; Intini R; Salati M; Fenocchio E; Belli C; Borelli B; Brambilla M; Prete AA; Quarà V; Antista M; Fassan M; Morano F; Spallanzani A; Ambrosini M; Curigliano G; de Braud F; Zagonel V; Fucà G; Pietrantonio F
Eur J Cancer; 2021 Jun; 150():155-167. PubMed ID: 33901794
[TBL] [Abstract][Full Text] [Related]
33. Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers.
Evrard C; Messina S; Sefrioui D; Frouin É; Auriault ML; Chautard R; Zaanan A; Jaffrelot M; De La Fouchardière C; Aparicio T; Coriat R; Godet J; Silvain C; Randrian V; Sabourin JC; Guimbaud R; Miquelestorena-Standley E; Lecomte T; Moulin V; Karayan-Tapon L; Tachon G; Tougeron D
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457245
[TBL] [Abstract][Full Text] [Related]
34. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
André T; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Abdullaev S; Memaj A; Lei M; Dixon M; Kopetz S; Overman MJ
Ann Oncol; 2022 Oct; 33(10):1052-1060. PubMed ID: 35764271
[TBL] [Abstract][Full Text] [Related]
35. The Current and Evolving Role of Immunotherapy in Metastatic Colorectal Cancer.
Silva VS; Riechelmann RP; Mello CA; Felismino T; Taboada R
Curr Cancer Drug Targets; 2022 Aug; 22(8):617-628. PubMed ID: 35209820
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.
Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z
Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092
[TBL] [Abstract][Full Text] [Related]
37. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
38. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
Overman MJ; McDermott R; Leach JL; Lonardi S; Lenz HJ; Morse MA; Desai J; Hill A; Axelson M; Moss RA; Goldberg MV; Cao ZA; Ledeine JM; Maglinte GA; Kopetz S; André T
Lancet Oncol; 2017 Sep; 18(9):1182-1191. PubMed ID: 28734759
[TBL] [Abstract][Full Text] [Related]
39. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience.
Serpas Higbie V; Rogers J; Hwang H; Qiao W; Xiao L; Dasari A; Mola-Rudd K; Morris VK; Wolff RA; Raghav K; Huey R; Parseghian C; Willis J; Kopetz S; Overman MJ; Johnson B
Oncologist; 2022 Nov; 27(11):952-957. PubMed ID: 35946836
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting.
Malapelle U; Parente P; Pepe F; De Luca C; Pisapia P; Sgariglia R; Nacchio M; Gragnano G; Russo G; Conticelli F; Bellevicine C; Vigliar E; Iaccarino A; Covelli C; Balistreri M; Clemente C; Perrone G; Danza A; Scaramuzzi F; Fassan M; Troncone G; Graziano P
Cells; 2021 Jul; 10(8):. PubMed ID: 34440647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
